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Research in context 
What is already known about this subject?  
 Differentiating type 1 from type 2 diabetes when diagnosed over 30 years of age is 
difficult. There is a lack of robust clinical criteria and many patients in this age group 
with positive islet autoantibodies have a clinical phenotype of type 2 diabetes 
without rapid insulin requirement. 
 
 Recent research using novel genomic methods has suggested that over 42% of type 1 
diabetes occurs after age 30 and the phenotype remains severe with 89% insulin 
treated within 1 year of diagnosis. 
 
 Severe (near absolute) insulin deficiency is a hall mark of type 1 diabetes and defines 
treatment and education requirements. However the prevalence and characteristics 
of diabetes leading to severe insulin deficiency in older adults has not been 
previously reported.  
 
What is the key question?  
 What is the prevalence and characteristics of type 1 diabetes defined by severe 
endogenous insulin deficiency diagnosed after age 30, and in clinical practice are 
these patients identified and managed as having type 1 diabetes? 
 
What are the new findings?  
 21% of participants with insulin treated diabetes diagnosed after 30 had severe 
insulin deficiency. These participants had similar clinical, islet autoantibody and 
genetic characteristics to a comparison cohort with young onset type 1 diabetes. 
 
 38% of those with absolute insulin deficiency did not receive insulin treatment at 
diagnosis. 
 Rapid insulin requirement was highly predictive of severe endogenous insulin 
deficiency: 85% required insulin within 1 year of diagnosis, and 57% of those 
progressing to insulin within 3 years of diagnosis had type 1 diabetes.  
 
How might this impact on clinical practice in the foreseeable future?  
 This study provides clear evidence that type 1 diabetes leading to severe, near 
absolute, insulin deficiency is common in later life but is often not recognised in 
clinical practice. We show that clinicians should strongly consider type 1 diabetes 
where a person previously classified as having type 2 requires insulin within 3 years 
of diabetes diagnosis.  
 
  
Abstract 
Aims/ hypothesis 
Late onset type 1 diabetes can be difficult to identify. Measurement of endogenous insulin secretion, 
using C-peptide, provides a gold standard classification in longstanding diabetes that closely relates 
to treatment requirements. We aimed to determine the prevalence and characteristics of type 
1 diabetes defined by severe endogenous insulin deficiency after age 30 and assess whether 
these patients are identified and managed as having type 1 diabetes in clinical practice. 
Methods 
We assessed the characteristics of type 1 diabetes defined by rapid insulin requirement 
(within 3 years of diagnosis) and severe endogenous insulin deficiency (non-fasting C-
peptide <200pmol/l) within 583 participants with insulin treated diabetes diagnosed after 
age 30 from the DARE population cohort. We compared characteristics with participants 
with retained endogenous insulin secretion (>600pmol/L) and 220 participants with severe 
insulin deficiency diagnosed under age 30.  
Results 
Twenty one percent of participants with insulin treated diabetes diagnosed after age 30 met 
study criteria for type 1 diabetes. Of these participants, 38% did not receive insulin at 
diagnosis, of whom 47% self-reported type 2 diabetes. Rapid insulin requirement was highly 
predictive of severe endogenous insulin deficiency: 85% required insulin within 1 year of 
diagnosis, and 57% of those progressing to insulin within 3 years of diagnosis had type 1 
diabetes. Participants with late onset type 1 diabetes defined by development of severe 
insulin deficiency had similar clinical characteristics to those with young onset type 1 
diabetes. However those with later onset type 1 diabetes had modestly lower type 1 
diabetes genetic risk score (0.268 vs 0.279, p<0.001, expected type 2 diabetes population 
median 0.231), higher islet autoantibody prevalence (GAD, IA2 or ZnT8 positive 78 vs 62% at 
13 vs 26 years diabetes duration, p=0.02), and were less likely to identify as having type 1 
diabetes (79 vs 100%, p<0.001).   
Conclusion 
Type 1 diabetes diagnosed over 30 years of age, defined by severe insulin deficiency has 
similar clinical and biological characteristics to when occurring at younger ages, but is 
frequently not identified. Clinicians should be aware that patients progressing to insulin 
within 3 years of diagnosis have a high likelihood of type 1 diabetes, regardless of initial 
diagnosis.  
 
  
Introduction 
Type 1 diabetes  is classically defined by autoimmune or idiopathic B-cell destruction leading 
to severe insulin deficiency[1] but this aetiopathalogical definition is difficult to apply in 
clinical practice. Definitions based on clinical criteria have been little investigated in adults 
and are poorly defined, with many features commonly thought of as discriminatory having 
no evidence base[2].  As a result there is no robust evidence based guidance on identifying 
type 1 diabetes in later life. Recent novel population based genetic stratification analysis has 
suggested at least  42% of type 1 diabetes  occurs after age 30[3]. This research suggests 
late type 1 diabetes  has similar characteristics to young onset disease and in contrast to 
classification defined by autoantibody status alone, continues to have a severe phenotype: 
89% were treated with insulin within one year, and 11% developed ketoacidosis[4]. 
However this technique does not allow classification of type 1 diabetes at an individual 
level, and neither islet autoantibodies or measures of endogenous insulin secretion were 
available. 
Measurement of C-peptide, a surrogate marker of insulin secretion, allows robust diagnosis 
of type 1 diabetes  in longstanding diabetes (>3 years duration) that closely relates to 
treatment requirements[5]. The development of severe (near absolute) insulin deficiency 
(commonly defined by stimulated C-peptide <200pmol/L) results in high glucose variability, 
marked hypoglycaemia risk, absolute insulin requirement and poor glycaemic response to 
non-insulin therapies[5, 6]. Therefore those with severe insulin deficiency will require 
glycaemic management according to type 1 diabetes guidelines regardless of disease 
aetiology. The prevalence and characteristics of diabetes leading to severe insulin deficiency 
in older adults is not known. 
We aimed to determine the prevalence and characteristics of type 1 diabetes defined by 
severe endogenous insulin deficiency after age 30 in patients with insulin treated diabetes, 
and assess whether these patients are identified and managed as having type 1 diabetes in 
clinical practice. 
  
Methods 
We assessed the prevalence and characteristics of type 1 diabetes defined by early insulin 
requirement and severe endogenous insulin deficiency in an insulin treated population 
cohort. 
Participants: 583 participants from the population based Exeter DARE (Diabetes Alliance for 
Research in England) cohort (http://exeter.crf.nihr.ac.uk/node/87) met the following inclusion 
criteria:  diagnosed with diabetes after age 30, insulin treated and measured C-peptide. 
Participants with previous pancreatic pathology (n=2) were excluded from analysis. To allow 
comparison with young onset type 1 diabetes we assessed a further cohort of 220 DARE 
participants diagnosed before age 30, meeting study criteria for type 1 diabetes (see below).  
Non-fasting (random) C-peptide, islet autoantibodies (GAD, ZNT8, IA2) and a type 1 diabetes 
genetic risk score (T1DGRS) were assessed in all included participants at mean 16 years 
duration, as previously described (see ESM methods)[6, 7]. Where multiple C-peptide 
measurements were available (70% of participants, median 3 values per participant) the 
median value was used. 
The DARE study was approved by the South West ethics committee (UK). Participants 
gave informed consent. 
Definition of diabetes type  
Type 1 diabetes was defined as continuous insulin treatment commenced within 3 years of 
diagnosis and severe insulin deficiency defined by a non-fasting C-peptide <200pmol/L.  
Insulin treated type 2 diabetes was defined as participants currently insulin treated with a C-
peptide ≥600pmol/L and a duration of diabetes at C-peptide measurement of over 3 years. 
Participants insulin treated and with a C-peptide level ≥200-<600pmol/l (n=115, median 48 
months to insulin therapy) were considered indeterminate and were not included in analysis 
(ESM figure 1).[5]  
Statistical analysis  
 
Data were assessed visually for distribution. All continuous variables except age were not 
normally distributed data therefore is presented as median and IQR. We compared the 
clinical characteristics, islet autoantibody status and T1DGRS of participant groups defined 
by C-peptide, initial insulin treatment and age of diagnosis using the Wilcoxon rank-sum test 
for continuous variables and χ2 analysis for comparison of categorical characteristics. All 
analyses were performed using Stata 15 (StataCorp LP, Texas). 
 
Results  
Severe insulin deficiency occurs in 21% of insulin treated patients diagnosed after age 30, 
and has similar clinical characteristics to young onset type 1 diabetes 
Twenty one percent (123/583) of insulin treated participants diagnosed with diabetes after 
30 years of age met the study criteria for type 1 diabetes with severe endogenous insulin 
deficiency (insulin treatment within 3 years and C-peptide<200pmol/L) (ESM figure 1).  
The characteristics of participants with late onset (>age 30) type 1 diabetes, in comparison 
to young onset (≤age 30) disease, and late onset type 2 diabetes (retained endogenous 
insulin secretion) are shown in table 1.  Participants with late onset type 1 diabetes defined 
by development of severe insulin deficiency had broadly similar characteristics to those with 
young onset type 1 diabetes: BMI, insulin dose and HbA1c did not differ. However those 
with later onset type 1 diabetes had modestly lower T1DGRS (0.268vs0.279, expected type 2 
diabetes population median 0.231[8]), higher islet autoantibody prevalence (78vs62%, at 
13vs26 years duration), and were more likely to be treated (Oral hypoglycaemic agent use 
15vs5%, initial insulin 62vs96%) and identify as having T2D (79vs100%).  
Classical clinical criteria cannot reliably identify patients with late onset type 1 diabetes 
leading to severe insulin deficiency 
Despite similar clinical features to young onset type 1 diabetes, classical clinical criteria 
could not robustly identify late onset type 1 diabetes. Only 41% had a BMI <25, and 28% of 
participants with BMI <25 had type 2 diabetes.  UK National Institute of Clinical Excellence 
guidance for type 1 diabetes identification (age of diagnosis <50 or BMI <25 kg/m2) 
identified 81% of type 1 diabetes but had very low specificity (41%). The specificity of these 
criteria would be far lower had non-insulin treated individuals been included in this cohort. 
Thirty eight percent of participants with late onset type 1 diabetes do not receive insulin 
at diagnosis  
These participants commenced insulin a median of 12 months from diagnosis, and had 
similar characteristics to those commencing insulin at diagnosis (ESM table 1). However only 
51% reported a diagnosis of type 1 diabetes, and 30% received co-treatment with oral 
glucose lowering therapy, in marked contrast to the 7% in those receiving insulin from 
diagnosis p<0.01. 
Early progression to insulin is a strong predictor of future severe insulin deficiency  
Eighty five percent (104/123) of all participants meeting criteria for T1D in this cohort 
were treated with insulin within 1 year of diagnosis versus 18% (55/306) of those meeting 
criteria for type 2 diabetes, and 77% (36/47) with an intermediate C-peptide. 57% of those 
progressing to insulin within 3 years of diagnosis met study criteria for type 1 diabetes 
(figure 1).  Severe insulin deficiency was rare in those progressing to insulin after 3 years, 
occurring in only 10 of 231 participants (4%).   
30% of those starting insulin at diagnosis after age 30 have type 2 diabetes by C-peptide 
criteria  
Despite clear clinical, biochemical and genetic characteristics of type 2 diabetes, 25% of 
these patients reported a diagnosis of type 1 diabetes and only 59% received concurrent 
oral glucose lowering therapy at a median 10 years diabetes duration (ESM table 2). 
 
  
Discussion 
To our knowledge, this is the first population analysis evaluating the prevalence of type 1 
diabetes defined by low endogenous insulin secretion. Our study shows that late onset 
type 1 diabetes with severe endogenous insulin deficiency is relatively common (21% of 
insulin treated patients), has very similar characteristics to young onset type 1 diabetes, 
but is frequently initially treated as type 2 diabetes. The majority of participants 
progressing to insulin within 3 years had type 1 diabetes and severe endogenous insulin 
deficiency, but this was often unrecognised 
Our finding that the clinical features of those with late onset type 1 diabetes are similar to 
young onset type 1 diabetes is consistent with recent research using a novel genetic 
stratification methodology[3]. This showed that 89% of those with genetically defined type 1 
diabetes occurring after age 30 required insulin within a year, strikingly similar to the 85% 
we report using a C-peptide based definition. This is in contrast to diabetes defined solely by 
islet autoantibody status where the phenotype appears intermediate between classical type 
1 diabetes and type 2 diabetes in this age group[4].  
A limitation of this study is the cross-sectional design within a relatively homogenous, 
geographically restricted population. Time to insulin and age of diagnosis were self-
reported, and participants assessed a median 13 years after diagnosis, meaning islet 
autoantibody positivity will be lower than that found at diagnosis [9] Negative autoantibody 
tests in this context therefore do not exclude autoimmune diabetes, and we consider it 
likely that the aetiology of antibody negative participants with low C-peptide will be 
autoimmune, as suggested by the high T1DGRS of these participants (median 0.262). The 
longer duration at islet autoantibody measurement in our young onset cohort is likely to 
explain the higher rate of islet autoantibody positivity observed in late onset diabetes in this 
cohort. A further limitation of this study is the lack of availability of a concurrent glucose 
when C-peptide was measured: this test may be reduced in the presence of 
hypoglycaemia [10]. A final limitation is that we included those within 3 years of diagnosis 
and C-peptide <200pmol/L in our type 1 definition. As C-peptide may be preserved in early 
type 1 diabetes a duration over 3 years was required where C-peptide was retained, 
potentially biasing prevalence estimates. Had we excluded the 19 patients meeting type 1 
criteria with duration <3 years our prevalence would be modestly lower at 18%. 
These results have clear implications for clinical practice.  Our results show type 1 diabetes 
leading to endogenous insulin deficiency is common in later life but is difficult to identify. 
Consistent with this many participants with type 1 diabetes in our cohort were diagnosed 
and treated as type 2 diabetes. Without a diagnosis of type 1 diabetes a patient will not 
receive appropriate education and will not be eligible for interventions that are often 
restricted to type 1 diabetes, such as carbohydrate counting, continuous glucose monitoring 
and insulin pump therapy. They will be at risk of ketoacidosis if insulin is withdrawn. Our 
results suggest that where patients are treated as type 2 diabetes but progress to insulin 
within 3 years of diagnosis, clinicians should reassess the underlying diagnosis, and strongly 
consider biomarker testing [5, 8, 11].  
Conclusion 
 
Type 1 diabetes defined by severe insulin deficiency has similar clinical and biological 
characteristics to type 1 diabetes occurring at younger ages, however patients are 
frequently diagnosed and treated as type 2 diabetes. Clinicians should be aware that 
patients progressing to insulin within 3 years of diagnosis have a high likelihood of type 1 
diabetes, regardless of initial diagnosis. 
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Figure Legends 
Figure 1: Comparison of time to insulin therapy up to 10 years post diagnosis in participants 
with severe endogenous insulin deficiency (C-peptide <200pmol/L) in black and retained 
endogenous insulin secretion (C-peptide≥600pmol/L) in grey. * 5th centile of a young T1D 
population corresponding to the 50th centile of a T2D population. 
Table 1: Comparison of the characteristics of those with insulin treated diabetes diagnosed 
over 30 years of age, between participants with severe endogenous insulin deficiency (C-
peptide <200 pmol/l) versus those with preserved insulin secretion (C-peptide >=600 
pmol/l) and those diagnosed 30 years and younger with severe endogenous insulin 
deficiency (C-peptide<200 pmol/l).   
 
 
 
  
 
 
 
References 
 
1. American Diabetes A. 2. Classification and Diagnosis of Diabetes. Diabetes care 2017; 
40:S11-S24. 
2. Shields BM, Peters JL, Cooper C, Lowe J, Knight BA, Powell RJ, et al. Can clinical features be 
used to differentiate type 1 from type 2 diabetes? A systematic review of the literature. BMJ open 
2015; 5:e009088. 
3. Thomas NJ, Jones SE, Weedon MN, Shields BM, Oram RA, Hattersley AT. Frequency and 
phenotype of type 1 diabetes in the first six decades of life: a cross-sectional, genetically stratified 
survival analysis from UK Biobank. Lancet Diabetes Endocrinol 2017. 
4. Pozzilli P, Di Mario U. Autoimmune diabetes not requiring insulin at diagnosis (latent 
autoimmune diabetes of the adult): definition, characterization, and potential prevention. Diabetes 
care 2001; 24:1460-1467. 
5. Jones AG, Hattersley AT. The clinical utility of C-peptide measurement in the care of patients 
with diabetes. Diabetic medicine : a journal of the British Diabetic Association 2013; 30:803-817. 
6. Hope SV, Knight BA, Shields BM, Hill AV, Choudhary P, Strain WD, et al. Random non-fasting 
C-peptide testing can identify patients with insulin-treated type 2 diabetes at high risk of 
hypoglycaemia. Diabetologia 2018; 61:66-74. 
7. Grubb AL, McDonald TJ, Rutters F, Donnelly LA, Hattersley AT, Oram RA, et al. A Type 1 
Diabetes Genetic Risk Score Can Identify Patients With GAD65 Autoantibody-Positive Type 2 
Diabetes Who Rapidly Progress to Insulin Therapy. Diabetes care 2018. 
8. Oram RA, Patel K, Hill A, Shields B, McDonald TJ, Jones A, et al. A Type 1 Diabetes Genetic 
Risk Score Can Aid Discrimination Between Type 1 and Type 2 Diabetes in Young Adults. Diabetes 
care 2016; 39:337-344. 
9. Williams GM, Long AE, Wilson IV, Aitken RJ, Wyatt RC, McDonald TJ, et al. Beta cell function 
and ongoing autoimmunity in long-standing, childhood onset type 1 diabetes. Diabetologia 2016; 
59:2722-2726. 
10. Hope SV, Knight BA, Shields BM, Hattersley AT, McDonald TJ, Jones AG. Random non-fasting 
C-peptide: bringing robust assessment of endogenous insulin secretion to the clinic. Diabetic 
medicine : a journal of the British Diabetic Association 2016; 33:1554-1558. 
11. Bingley PJ. Clinical applications of diabetes antibody testing. The Journal of clinical 
endocrinology and metabolism 2010; 95:25-33. 
 
 
  
 
